No profile data available.
Pulmonx Corporation (LUNG) is a healthcare company in the targeted healthcare equipment industry, based in Redwood City, United States, with about 296 full-time employees.
It reported revenue of $90.50 million for fiscal year 2025, up 8.0% from fiscal year 2024, and net income of -$54.00 million. United States was its largest region in fiscal year 2025, with 63% of revenue. Its market capitalization was $77.72 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease.
Pulmonx reported $90.50 million in revenue for fiscal year 2025, up 8.0% from $83.79 million in fiscal year 2024.
United States: 63% of revenue by region in fiscal year 2025, followed by Europe, Middle-East and Africa (30%).
$77.72 million as of October 9, 2026.
Listed companies of a similar size in the same industry (targeted healthcare equipment) include NeurAxis, Inc. (NRXS), Outset Medical, Inc. (OM), Lensar, Inc. (LNSR), RetinalGenix Technologies Inc. (RTGN).